Because the liver is a multifunctional and a vital organ for survival, the management of acute liver failure requires the support of a huge number of metabolic functions performed by the organ. Many early detoxification-based artificial liver techniques failed to treat the patients owing to the inadequate support of the many essential hepatic functions. For this reason, a bioartificial liver (BAL) comprising of viable hepatocytes on a mechanical support is believed to more likely provide these essential functions than a purely mechanical device. From 1990, nine clinical studies of various BAL systems have been reported, most of which utilize a hollow fiber technology, and a much larger number of various BAL systems have been suggested to show an enhanced performance. Safety issues such as immunological reactions, zoonosis and tumorgenicity have been successfully addressed for regulatory approval, but a recent report from a large-scale, randomized, and controlled phase III trial of a leading BAL system (HepatAssist) failed to meet our expectation of efficacy in terms of the overall survival rate. In this paper, we review the current BAL systems actively studied and discuss critical issues such as the hepatocyte bioreactor configuration and the hepatocyte source. On the basis of the insights gained from previously developed BAL systems and the rapid progress in stem cell technology, the short-term and long-term future perspectives of BAL systems are suggested.
Because the liver is a multifunctional and a vital organ for survival, the management of acute liver failure requires the support of a huge number of metabolic functions performed by the organ. Many early detoxification-based artificial liver techniques failed to treat the patients owing to the inadequate support of the many essential hepatic functions. For this reason, a bioartificial liver (BAL) comprising of viable hepatocytes on a mechanical support is believed to more likely provide these essential functions than a purely mechanical device. From 1990, nine clinical studies of various BAL systems have been reported, most of which utilize a hollow fiber technology, and a much larger number of various BAL systems have been suggested to show an enhanced performance. Safety issues such as immunological reactions, zoonosis and tumorgenicity have been successfully addressed for regulatory approval, but a recent report from a large-scale, randomized, and controlled phase III trial of a leading BAL system (HepatAssist) failed to meet our expectation of efficacy in terms of the overall survival rate. In this paper, we review the current BAL systems actively studied and discuss critical issues such as the hepatocyte bioreactor configuration and the hepatocyte source. On the basis of the insights gained from previously developed BAL systems and the rapid progress in stem cell technology, the short-term and long-term future perspectives of BAL systems are suggested.
[Key words: bioartificial liver, liver support, hepatocyte bioreactor, fulminant hepatic failure, liver transplantation]
Although both acute and chronic liver failure patients can be treated effectively by whole-organ transplantation, there are only approximately 4000 donor livers available in the United States annually, while approximately 30,000 patients die from liver failure (1) (2) (3) , and almost 20,000 patients are currently awaiting an available donor liver (liver waiting list, United Network for Organ Sharing, 2003, available at www.unos.org). Furthermore, despite the recent advances in supportive therapies, patients with severe fulminant hepatic failure (FHF) have a mortality rate of approximately 90% (4) . If essential liver functions can be restored during the critical phase of liver failure, either by artificial or auxiliary methods, it should be possible to improve the survival rate of these patients. Therefore, more donor livers will be available and costly transplantation procedures can be avoided (5) . Various nonbiological approaches, such as hemodialysis, hemoperfusion, plasmapheresis and plasma exchange, have had a limited success because of the insufficient replacement of the synthetic and metabolic functions of the liver in these systems (6) (7) (8) (9) . On the other hand, extracorporeal biological treatments including whole-liver perfusion, liver slice perfusion and cross hemodialysis, have shown some beneficial results, but they are difficult to implement in a clinical setting (10) (11) (12) .
For these reasons, many investigators have attempted to develop various extracorporeal bioartificial liver (BAL) systems. Typically, a BAL system incorporates a hepatoma cell line or isolated primary hepatocytes into a bioreactor in which the cells are immobilized, cultured and induced to perform the hepatic functions by processing the blood or plasma of liver failure patients (13, 14) . The BAL system is expected to act as a bridge that provides patients with more time until a donor organ can become available for transplantation or until their own liver can be regenerated (15) .
There are many available reviews that describe the history, general bioreactor and system designs, the preclinical and clinical results of current BAL systems (16) (17) (18) (19) (20) . Therefore, in this paper, we focus on the developmental trends of the elements of the BAL system including cell sources, the cell mass, perfusion type, and culture methods adopted in a bioreactor. Finally, on the basis of the insight gained from current BAL systems and the rapid progress in stem cell technology, the short-term and long-term future perspectives of the BAL systems will be given.
BIOREACTOR CONFIGURATIONS OF BAL SYSTEMS IN CLINICAL TRIAL
From 1990, nine BAL systems have been clinically tested, most of which utilize a hollow fiber technology, and a much larger number of BAL systems in preclinical tests have been suggested to show an enhanced performance. Among the nine clinically tested BAL systems, three (21-23) have a bioreactor configuration similar to that of HepatAssist (Circe Biomedical, Lexington, MA, USA) (24) . Therefore, in this paper, we review the bioreactors of the other six BAL systems. The characteristics and major clinical findings are listed in Table 1 .
The extracorporeal liver assist device (ELAD) is the only BAL system that uses the human hepatocyte cell line C3A, which is derived from the hepatoma cell line HepG2 (25) (26) (27) . C3A cells express normal liver specific pathways such as ureogenesis, gluconeogenesis and cytochrome P-450 activities, and produce albumin and a-fetoprotein (28) . The cells are grown in the extracapillary space of cartridges and blood flows through the lumen of hollow fibers. A portion of the patient's plasma is ultrafiltrated through a membrane (70 kD) and is in direct contact with the C3A cells. In an uncontrolled clinical trial (26), 6 out of 11 patients died, while one patient completely recovered without an orthotopic liver transplantation (OLT) and four patients underwent a successful OLT after a mean treatment of 40.8 h. In a pilot controlled trial on 24 acute liver failure patients, there was no significant difference in survival rate, renal function, and biochemical parameters between the ELAD-treated patients and the controls (27) . In contrast, the plasma ammonia and bilirubin level were higher than those before the ELAD treatment.
The HepatAssist system developed by Demetriou and coworkers was examined in the largest controlled clinical trial (29) (30) (31) (32) (33) (34) . In this system, microcarrier-attached cryopreserved porcine hepatocytes are placed in the extracapillary space (29) . They particularly use 0.2 mm-pore hollow fiber membranes. This size is sufficiently small to block the passage of whole cells. Plasma is separated by continuous centrifugation. It first passes through an activated charcoal column and flows through the lumen of the hollow fibers. In the phase I of a clinical study, 18 patients with FHF were supported with the system (29, 31) . Sixteen patients had a successful liver transplant and were discharged with normal neurological states and one patient was bridged to recovery without requiring a transplant. In another clinical study, the BAL system treatment resulted in some improvement in the patients' neurological states, intracranial pressure (ICP), and biochemical parameters (35) . Both the total bilirubin and ammonia concentrations decreased by 18% of the initial concentrations. However, porcine endogenous retrovirus (PERV) transmission was confirmed after the BAL system treatment but there was no evidence of viral transmission from porcine hepatocytes to patients (17) .
The liver support system (LSS) developed by Gerlach and coworkers in Berlin consists of a unique bioreactor with four different capillary membranes, which are woven into a 3-D lattice (36, 37) . These capillaries independently and locally provide oxygen, nutrients and plasma perfusate inflow and outflow to hepatocytes. The bioreactor enables the spontaneous aggregation of parenchymal cells in a cocultured with nonparenchymal cells, forming tissue-like structures. The formation of bile canaliculi and bile duct-like structures and a neospace of Disse with a biomatrix produced was demonstrated. The LSS is the only system that uses primary human hepatocytes isolated from discarded donor livers as well as porcine hepatocytes (38) . In phase I of a study using human hepatocytes, the LSS was combined with a single-pass albumin dialysis device (MARS), called the modular extracorporeal liver support (MELS) (38) . Both BAL systems, LSS and MELS, successfully supported each six patients, who were all transplant candidates, until an OLT and improved their neurological and coagulation states.
The bioartificial liver support system (BLSS), which was developed in Pittsburgh and commercialized by Excorp Medical (Minneapolis, MN, USA), uses cellulose acetate hollow fibers with a 100 kD-molecular weight cut-off (MWCO) (39, 40) . Primary porcine hepatocytes (70-120 g) are mixed with 20% vol/wt of a 3.1% collagen solution and the mixture is infused into the extracapillary space. The blood ammonia levels decreased by 33% compared with the initial levels. However, the patients' neurological states are not improved significantly (40) .
The radial flow bioreactor (RFB) BAL system was developed in the University of Ferrara, Italy (41, 42) . In this system, the patients' plasma passes from the center to the periphery of the module. Oxygen consumption rate is measured to evaluate the function of the bioreactor; when the rate decreases during the treatment of a patient, it indicates the necrosis of hepatocytes. The RFB-BAL system decreased the mean ammonia and bilirubin levels by 33% and 11%, respectively (42) .
The Academic Medical Center (AMC) BAL system developed by Chamuleau and coworkers in the University of Amsterdam, the Netherlands, consists of a nonwoven hydrophilic polyester matrix for cell attachment and hollow fibers for oxygen supply and a spacer between the matrix (43) (44) (45) (46) . The matrix, with a thickness of 4 mm and a total surface area of 5610 cm 2 , is spirally wound with longitudinal hollow fibers. In the AMC-BAL reactor, the plasma of the patient and small hepatocytes aggregates are in direct contact, resulting in an optimal mass transfer and an optimal oxygen supply is achieved by hollow fibers in the bioreactor. Six out of seven patients were successfully supported until an OLT. An improved urine output was noted in patients with renal insufficiency. After the AMC-BAL treatment, the plasma ammonia and bilirubin concentrations decreased by 44% and 31%, respectively (46) .
In the aspect of hepatic function performance, the HepatAssist system has three important disadvantages. First, it uses a relatively small amount of cryopreserved hepatocytes, 5% of the liver mass. Second, treatment time is very short, 6-8 h. In most other BAL systems, patients are supported for at least 12 to 24 h. Third, the mass transfer between hepatocytes and plasma occurs by only diffusion and back filtration through the hollow fiber membrane in the bioreactor. The other five systems use more than 10 billion hepatocytes (10% of the liver mass), and in the RFB-BAL, MELS, and AMC-BAL systems, the patients' plasma is in direct contact with hepatocytes. The major factor that influences mass transfer efficiency between the BAL systems and liver failure patients is plasma or blood exchange rates, ranging from 22 to 50 ml min -1 and 150 to 250 ml min -1 for plasma and blood, respectively. The plasma exchange rates of the RFB-BAL (22 ml min -1 ) and MELS (31 ml min -1 ) systems are low when their cell mass is considered.
It is very difficult to compare their performance or choose the best one among the six BAL systems, due to the complexity of patient groups, the different perfusion types, and other conditions in a clinical setting. However, considering only the performance-specific parameters, such as cell mass and mass transfer rate, the RFB, MELS, and AMC-BAL systems might have a higher performance than the others. On the other hand, the others can be evaluated as safer than these three high-performance systems.
The cell density of a bioreactor in a BAL system is extremely high. In addition, hepatocytes are one of high oxygen-consuming cells in the culture (47) . Therefore, oxygen supply into the bioreactor is a very important design parameter. Only the MELS and AMC-BAL systems have an integral oxygenation system in the bioreactor; the others have a separate oxygenator placed immediately before the bioreactor. The integral oxygenator eliminates the hypoxic space and reduces dissolved oxygen gradient between the inlet and outlet ports. When plasma or blood perfusion flow rate is inadequate, the bioreactor type with an integral oxygenator is recommended to prevent hypoxia of the reactor outlet portion.
Because the viability and functional activities of hepatocytes vary considerably after cell loading and during the BAL treatment, it is very important to monitor their viability and various functions to estimate their microenvironment and to determine the possible treatment time. However, the monitoring results of cellular activities have not been reported or have been often neglected. Therefore, decreases in the bioreactor activities during the treatment of a patient must be checked and the activity information is considered to improve the bioreactor because it was reported that plasma from liver failure patients is very harmful to cultured hepatocytes (48, 49) .
BAL SYSTEMS IN PRECLINICAL OR IN VITRO TEST
In addition to the above-mentioned BAL systems in clinical studies, various different BAL systems have been investigated and examined for their in vitro and in vivo performance. Here, eight noteworthy BAL systems are considered. Their unique bioreactor configurations are demonstrated schematically in Table 2 . The LIVERx2000 systems have already entered the clinical study phase. However, because their clinical results have not been reported until to date, the BAL system is described in this section.
The LIVERx2000 system was designed and developed by Hu et al. in the Minnesota University and commercialized by Algenix (St. Paul, MN, USA) (50, 51) . The hepato-cytes suspended in a collagen gel are injected into the lumen of a hollow fiber with an MWCO of 100 kD and the extracapillary compartment is perfused with a recirculating medium. After 24 h, the gel contracts, creating a third space, which is now perfused with the medium, and the extrafiber space is perfused with whole blood.
The LIVERAID BAL system was developed by Arbios System (Los Angeles, CA, USA) founded by the principal investigator of the HepatAssist system (the information was available at the web of Arbios System Inc., http://www. arbios.com). This BAL system utilizes a multicompartment hollow fiber module with a unique fiber-within-fiber geometry. This geometry allows for the integration of liver cell therapy and blood detoxification within a single module.
The oxygenating hollow fiber bioreactor (OXY-HFB) BAL system was developed by Jasmund et al., in Eberhard Karls University, Germany (52) . The OXY-HFB BAL system consists exclusively of oxygenating and integral heat exchange fibers with a simple and effective design. Primary liver cells are seeded on the surface of the fibers in the extrafiber space. Oxygen requirements are supplied and temperature is controlled via the fibers. Plasma from patients is perfused through an extrafiber space and brought into direct hepatocellular contact.
The liver lobule-like structure module (LLS) BAL system, which was designed by Mizumoto and Funatsu in Kyushu University, has many hollow fibers that act as a blood capillary and are regularly arranged close to each other (53) . Hepatocytes are inoculated by a centrifugal force, at a high density in the outer space of the hollow fibers.
They form an organoid and perform many liver-specific functions.
The UCLA-BAL system developed by Dixit and Gitnick, in UCLA, involves the direct hemoperfusion of microencapsulated hepatocytes in an extracorporeal chamber (54) . The hepatocytes are located in biocompatible and semipermeable calcium alginate-ploylysins-sodium alginate composite membranes where they can freely interact in various biological reactions. Simultaneously, the microencapsulated hepatocytes are also immunoisolated from the components of blood elements, thereby preventing any adverse immunological reactions. Microcapsules have a high surface area, a high capacity for hepatocytes, and a high membrane permeability. All these characteristics should result in a more effective and efficient metabolic exchange of metabolites with hepatocytes.
We have developed an alginate-entrapped hepatocyte spheroid (AHS) BAL system, which has a configuration similar to that of the UCLA-BAL system (3). However, the porcine hepatocytes are suspension cultured for 20 h to form spherical aggregates, called spheroids, before entrapment. In previous in vitro studies, hepatocyte spheroids have a higher performance of liver-specific functions than dispersed single hepatocytes, particularly detoxification in plasma or serum (55) . A large-scale and a high-yield preparation of hepatocytes spheroids were achieved using special media and a culture vessel. These hepatocyte spheroids were immobilized in Ca-alginate beads using a high-capacity solution dropping apparatus within 20 min. The performance of the AHS-BAL system was actively evaluated at anhepatic pigs (data not shown).
The multicapillary polyurethane foam module (PUF) BAL system developed by Kyushu University consists of a cylindrical PUF block with many capillaries in a triangular arrangement to form a flow channel (56) . The diameter of each capillary is 1.5 mm, and the capillaries are arranged at a 3.0 mm pitch. The inoculated hepatocytes located in the pores formed 100-150-mm diameter spheroids within 24 h.
The flat membrane bioreactor BAL system developed by de Bartolo et al., in Eberhard Karls University, Germany (57), and Shito et al. (58) in Masachusetts General Hospital consists of a multitude of stackable flat membrane modules, each having an oxygenating surface area. The bioreactor is prepared for cell culture by coating the oxygen-permeable membrane with type I collagen. After the seeding and attachment of hepatocytes, a second matrix layer of collagen is placed on the top of the cell layer. This unique culture configuration is called a "sandwich culture" which is the most stable culture method for hepatocytes (59) .
In observing the above eight new different BAL systems, two notable trends of the bioreactor design for the BAL systems are recognized. One is that an additional channel for nutrients or oxygen supply is integrated into the bioreactor (LIVERx2000, LIVERAID, Oxy-HFB, and FMB-BAL). The other is that more improved hepatocyte culture techniques, such as the use of spheroids, cylindrical organoids, and sandwich culture, are applied for long-term and enhanced liver functions (LLS-BAL, AHS-BAL, PUF-BAL, and FMB-BAL).
HEPATOCYTE CULTURE TECHNIQUES AND BAL SYSTEMS
In the liver, hepatocytes have a distinctive epithelial polarity and cell-cell communication structures including bile canaliculi, a tight junction, and a gap junction, and also show highly efficient regeneration and differentiated functions (60, 61) . However, they lose very quickly these characteristics when cultured in vitro (62) . Therefore, there have been many difficulties in the culture of hepatocytes. Research carried out to date on the long-term culture of hepatocytes can be classified into two strategies, the optimization of the extracellular matrix environment and the control of cell-cell interactions.
In the early BAL systems of developed by Matsumura et al. (63) and Margulis et al. (64) , no special hepatocyte culture techniques were applied to BAL systems; only a cell suspension was used. Thereafter, microcarriers (29) and collagen (39) were used as hepatocyte culture substrates in the bioreactors. More advanced culture techniques including microencapsulation, the use of porous matrixes, spheroids and organoids, collagen sandwich culture and coculture (65, 66) have been investigated and applied to make high-performance bioreactors, which play a key role in the BAL system. In the near future, a high-performance BAL system in which hepatocytes are cultured as spheroids (PUF-HALSS), organoids (LLS-HALSS), or a sandwiched monolayer (FMB) will be subject to clinical trials. More improved clinical results are expected. Various culture methods and their application states to BAL systems are summarized in Table 3 .
SOURCE OF HEPATOCYTES
Cellular component of most BAL systems in clinical and preclinical studies rely on primary porcine hepatocytes in spite of the finding that human primary hepatocytes are ideal for a BAL system. This is because the high demand for donor organs makes it unlikely that sufficient excess tissues would be available for nontransplantation application. Due to their easy availability and high functional activities, porcine cells are the second best choice until other human-origin hepatocytes are available.
In some countries including Korea, to solve the severe shortage of donor organs, a xenotransplantation project of breeding dedicated transgenic pigs has been established nationally. Furthermore, a BAL system using porcine hepa- tocytes is considered to be an optimal candidate for use in the investigation of the biological safety of porcine tissues under very controlled conditions. This idea is based on the fact that the contact with xenogenic cells will occur temporarily and without direct cell-cell contact. Therefore, pathogen-free and low immunogenic pigs may offer a good and safe hepatocytes source for a BAL system in the near future.
As another source of hepatocytes, established cell lines that can be sufficiently expanded have been approached by development tumor-derived cell lines (28) and immortalized cell lines, and their gene manipulations (67, 68) . The C3A subclone of HepG2 has already been used in clinical trials despite its poor liver functions. To enhance their weak or lost liver functions that are important for liver support, such as ammonia removal activity, the glutamine synthetase gene was transfected and transfected cells demonstrated a high ammonia removal activity in a bioreactor (68) .
Cells as promising sources of human hepatocytes for a BAL system in the future are classified into two types according to the site of origin. One is intrahepatic stem cells and the other is extrahepatic stem cells. Intrahepatic stem cells include mature hepatocytes (69, 70) , oval cells (71), small hepatocytes (72, 73) , hepatoblasts (74) , and hepatocyte-colony-forming units in culture (H-CFU-C) (75, 76) , whereas extrahepatic stem cells include hematopoietic stem cells (HSCs) (77, 78) and mesenchymal stem cells (MSCs) (79, 80) . It is believed that there is a close relationship between cell types in terms of their origin (e.g., oval cell vs HSCs).
A BAL system should be custom-made for emergency situations. Therefore, to use hepatic stem cells as a hepatocyte source, it will be necessary to cultivate them in large quantities and differentiate them into functional mature hepatocytes in vitro. Although the hepatic stem cells mentioned above may have differentiation potential from a basic scientific point of view, they must satisfy three requirements for applications. First, they must have a proliferative capacity of up to at least 10 billion cells (the minimal cell number for a BAL system) without a loss of differentiation potential. For this, it is believed that the bioreactor technology will be involved. Second, they must differentiate to functional mature hepatocytes with a maximal yield based on the precise lineage-specific differentiation protocol. Finally, the high cost arising from the use of expensive culture media, growth factors, and cytokines must be solved.
DISCUSSION
Recently, the first prospective, multicenter, randomized, controlled clinical trial of a HepatAssist system has been conducted on 171 patients in 11 U.S. and 9 European medical centers (81) . This trial did not achieve its primary endpoint (30-d survival rate) in the overall study population. For the entire patient population, the 30 d survival rate was 71% for the BAL treatment vs 62% for the control (P=0.26). However, when adjusting for the impact of the disease etiology and liver transplantation on the patients' survival, patients with fulminant and subfulminant hepatic failure treated with the BAL system had a statistically significant (P= 0.048) survival advantage compared to the controls receiving standard medical care. This clinical trial was a milestone in the history of BAL technology and gave a chance to carefully consider the requirements of a BAL system to support liver functions.
Recently, the membrane of the bioreactor and the reactor flow rate of the ELAD system has been modified from 70 kD to 120 kD and 200 ml min -1 to 500 ml min -1 , respectively (82) . More recently, the principal developers of the HepatAssist system fabricated an improved version of the HepatAssist system, the HepatAssist-2 system, which has specifications similar to those of their early BAL system except for the increased cell mass (http://www.arbios.com). The HepatAssist-2 system can accommodate 15 billion hepatocytes; 3 times that of the former BAL system. Moreover, the AMC-BAL system developed in Amsterdam Medical Center, which is the most novel noteworthy BAL system that has shown impressive phase I clinical results (46), uses 10 billion fresh (not cryopreserved) hepatocytes (twofold of the HepatAssist system), and the hepatocytes loaded in the bioreactor form small aggregates in the porous matrix. The hepatocyte aggregates are directly perfused with plasma without any immunological barriers. Gerlach in Germany designed the bioreactor of the LSS or MELS in the early 1990s (36) , similar to the HepatAssist system. This reactor can contain up to 500 g of hepatocytes, these cells form in vivo liver-like sinusoidal structures and plasma can be perfused via two independent compartment hollow fiber bundles. In addition, this BAL system is the only system that has been subjected to clinical studies using primary human hepatocytes derived from discarded donor livers. Therefore, their experience might provide useful information that may assist in the development of next-generation BAL systems that use human hepatocytes.
From these developments along with the characteristics of the modified ELAD, HepatAssist-2, AMC-BAL, MELS and other BAL systems, a large animal study of which has recently been completed, the following three trends can be identified. First, cell mass employed is increasing and most BAL systems use approximately 10 to 20 billion fresh hepatocytes. Second, immunological barriers are not a requirement for a BAL system. This is because the short-term contact with xenogenic cells does not induce any immunological complications, and the immunological barriers are frequently removed for the maximum mass transfer. Third, hepatocytes are cultured as an organoid with appropriate cell-cell interactions, which can enhance and prolong the hepatic functions.
Regarding hepatocyte cryopreservation, several cryopreservation methods for hepatocytes have been reported (83, 84) . However, hepatocyte functional activities after thawing are still unsatisfactory. The availability and logistics of BAL systems will be significantly improved if methods of long-term preservation of hepatocytes without a loss of cellular activity were developed. Therefore, until a preservation method is fully established, centralized regional liver support centers such as the Charite Center in Germany are needed to increase the frequency of supporting fulminant and subfulminant hepatic failure patients, up to two to three cases per week. At this frequency, the continuous maintenance of ready-to-use BAL systems may be reason- In developing a new BAL system, the design of bioreactors and evaluation are the most important and difficult procedures. However, there are a number of obstacles at each development step awaiting the inventor. The poor yield and viability of isolated hepatocytes, the unstable hepatic failure model of small and large animal (85) , the absence of a reversible FHF pig model (86) , the high research and utility cost for experiments, the strict safety regulations for xenogenic cell therapeutics (Guidance for industry: source animal, product, preclinical and clinical issues concerning the use of xenotransplantation product in humans. Final guidance, U.S. FDA, April 2003), and the difficult controlled clinical trials are the most common difficulties encountered in BAL system development. Nevertheless, the development of BAL systems is an interesting research field for cell culture and bioreactor engineers as well as medical practitioners.
Although there are still many obstacles to overcome, it is expected that highly functional human hepatocytes will become available within a decade with the development of stem cell technology. Hepatocytes derived from stem cells are first utilized for cell transplantation therapy. However, BAL systems also require human hepatocytes generated from stem cells. According to recent clinical results, BAL systems using porcine hepatocytes have proven to be safe, but immunological rejection and zoonosis still remain as major problems. If a sufficient number of human hepatocytes can be used as a cell source for BAL systems, the corresponding progress in bioreactor development and the better understanding of cell biology and the physiology of liver failure will allow the development of next-generation BAL system. The different characteristics of the present and nextgeneration BAL systems are listed in Table 4 .
If development of the BAL system were to progress and the system were to reach the level of the artificial kidney, it is expected that nobody will die from acute liver failure or due to a shortage of donor livers in the near future. Moreover, a diseased liver can be supported or substituted with new tissues generated by liver tissue engineering. 
